Holen Sie sich die Stockscreener-App
3.01
3.08%
0.09
Handel nachbörslich:
3.07
0.06
+1.99%
Schlusskurs vom Vortag:
$2.92
Offen:
$2.94
24-Stunden-Volumen:
114.17K
Relative Volume:
0.63
Marktkapitalisierung:
$134.97M
Einnahmen:
$8,000
Nettoeinkommen (Verlust:
$-32.15M
KGV:
-3.4758
EPS:
-0.866
Netto-Cashflow:
$-26.37M
1W Leistung:
+7.50%
1M Leistung:
+19.44%
6M Leistung:
-46.15%
1J Leistung:
+16.67%
1-Tages-Spanne:
$2.94
$3.1679
1-Wochen-Bereich:
$2.78
$3.1679
52-Wochen-Spanne:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.01 | 130.93M | 8,000 | -32.15M | -26.37M | -0.866 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Lake Street | Buy |
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Alle ansehen
Genelux Corp Aktie (GNLX) Neueste Nachrichten
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux president and CEO Zindrick Thomas sells $8,225 in stock By Investing.com - Investing.com Australia
Genelux CSO Yu Yong sells $1,798 of common stock - Investing.com UK
Genelux CSO Yu Yong sells $1,798 of common stock By Investing.com - Investing.com Nigeria
Genelux CTO Joseph Cappello sells $1,799 in company stock By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $804 in stock By Investing.com - Investing.com Nigeria
Genelux president and CEO Zindrick Thomas sells $8,225 in stock - Investing.com
Genelux CTO Joseph Cappello sells $1,799 in company stock - Investing.com
Genelux head of regulatory sells $804 in stock - Investing.com
Genelux (GNLX) CSO Yu Yong sells 605 shares to cover RSU tax bill - Stock Titan
Research Analysts Offer Predictions for Genelux Q2 Earnings - MarketBeat
GENELUX (GNLX) CEO Zindrick sells 2,798 shares for RSU tax obligations - Stock Titan
Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained - TipRanks
Genelux : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Ovarian cancer trial readout due in 2H26 as Genelux cash lasts to 1Q27 - Stock Titan
GENELUX Corp 1Q 2026: Revenue $0 Net loss $8.9M, EPS $(0.20) — 10-Q Summary - TradingView
Genelux (GNLX) raises $18.5M, extends cash runway into 2027 - Stock Titan
GNLX Stock Price, Quote & Chart | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
[ARS] GENELUX Corp SEC Filing - Stock Titan
Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan
Genelux (GNLX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Olvi Vec could reshape advanced ovarian cancer treatment, Genelux claims - Traders Union
Genelux Corporation (GNLX) Stock: Technical Signals (Technical Weakness) 2026-04-20Trending Volume Leaders - newser.com
Genelux advances next generation oncolytic immunotherapies for cancer treatment - Traders Union
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - MarketBeat
Is Genelux Corporation (GNLX) Stock Good for Short Term | Price at $2.45, Down 7.20%Elite Trading Signals - newser.com
GNLX Stock Analysis: Genelux Corporation Holds Near 2.57 Level With Modest Daily Gain - Newser
GNLX Technical Analysis & Stock Price Forecast - Intellectia AI
Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI
Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia
Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com
Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $1.4k in shares - investing.com
Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com South Africa
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genelux Corp-Aktie (GNLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cappello Joseph | Chief Technical Officer |
May 11 '26 |
Sale |
2.97 |
605 |
1,799 |
154,549 |
| Zindrick Thomas | President and CEO |
May 11 '26 |
Sale |
2.94 |
2,798 |
8,226 |
532,051 |
| Smalling Ralph | Head of Regulatory |
May 11 '26 |
Sale |
2.98 |
270 |
804 |
67,803 |
| Smalling Ralph | Head of Regulatory |
Mar 24 '26 |
Sale |
2.42 |
345 |
835 |
68,313 |
| Smalling Ralph | Head of Regulatory |
Mar 25 '26 |
Sale |
2.51 |
240 |
602 |
68,073 |
| Cappello Joseph | Chief Technical Officer |
Mar 24 '26 |
Sale |
2.42 |
906 |
2,193 |
155,154 |
| Yu Yong | SVP, Clinical Development |
Mar 24 '26 |
Sale |
2.42 |
906 |
2,193 |
144,938 |
| Zindrick Thomas | President and CEO |
Mar 24 '26 |
Sale |
2.42 |
3,582 |
8,668 |
534,849 |
| Thomas John | Director |
Mar 02 '26 |
Sale |
2.90 |
10,000 |
28,957 |
482,784 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):